Advertisement
J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


A more recent version of this article appeared on August 1, 2008

Papers In Press, published online ahead of print April 27, 2008
J. Lipid Res., doi:10.1194/jlr.M700374-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
M700374-JLR200v1
49/8/1682    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Masson, D.
Right arrow Articles by Assem, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Masson, D.
Right arrow Articles by Assem, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on August 21, 2007
Revised on April 3, 2008
Accepted on April 26, 2008

Activation of the constitutive androstane receptor decreases HDL in wild-type and human apoA-I transgenic mice

David Masson, Mohamed Qatanani, Anne laure Sberna, Rui Xiao, Jean Paul Pais de Barros, Jacques Grober, Valerie Deckert, Anne Athias, Philippe Gambert, Laurent Lagrost, David D. Moore, and Mahfoud Assem

Clinical and Administrative Pharmacy, University of Iowa, Iowa City, IA 52242

Corresponding Author: mahfoud-assem{at}uiowa.edu

The nuclear hormone receptor Constitutive Androstane Receptor (CAR, NR1I3) regulates detoxification of xenobiotics and endogenous molecules, and has been shown to be involved in hepatic bile acids and cholesterol metabolism. The goal of this study was to address potential effects of CAR on the metabolism of high density lipoprotein (HDL) particles, key components in the reverse transport of cholesterol to the liver. Wild type (WT) mice, transgenic mice expressing human apolipoprotein A-I (HuAITg) and CAR-deficient (CAR-/-) mice were treated with the specific CAR agonist 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP). CAR activation decreased HDL cholesterol and plasma apoA-I levels in both WT and HuAITg mice, but not CAR-/- mice. Both mouse apolipoprotein A-I and human apolipoprotein A-I were decreased by more than 40 % after TCPOBOP treatment, and kinetic studies revealed that production rate of HDL is reduced in TCPOBOP-treated, wild-type mice. In transient transfections, TCPOBOP-activated CAR decreased the activity of the human apoA-I promoter. Although loss of CAR function did not alter HDL levels in normal chow fed mice, HDL cholesterol, apoA-I concentration, and apoA-I mRNA levels were increased in CAR-/- mice relative to WT mice when both were fed a high fat diet. We conclude that CAR activation in mice induces a pronounced decrease in circulating levels of plasma HDL at least in part through down-regulation of apolipoprotein A-I gene expression.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement